Trametinib

The lung cancer cell lines A549, NCI-H358, NCI-H1792, NCI-H23, SW900 and SW1573 were purchased from the American Type Culture Collection. SK-LU-1, Calu-1, Calu-6 and NCI-H460 were provided by Takashi Takahashi (Nagoya University, Japan). RERF-LC-AD2, LU-65 and LU-99 cells were obtained from the Japanese Cell Research Bank (Osaka, Japan). HCC2108 cells were obtained from Korean Cell Line Bank (Seoul, South Korea). The NCI-H1573 and NCI-H2030 cells were provided from Massachusetts General Hospital Cancer Center. Cells were cultured in RPMI1640 (Invitrogen) with 10% FBS. Characteristic of cell lines used in this study were summarized in Supplementary Table S4. Cells were obtained between 2012 and 2016. Experiments using A549, SW900, LU-65 and HCC2108 cells were done within 6 months from the acquisition of these cells from cell banks. All other cell lines were tested and authenticated by short tandem repeat (STR) analysis with GenePrint 10 System (Promega) by the Japanese Cell Research Bank at the time of submission. Cells were regularly screened for Mycoplasma using a MycoAlert Mycoplasma Detection Kit (Lonza). NVP-BGJ398, GDC-0941, ABT-263, selumetinib, afatinib, and trametinib were obtained from Active Biochem. Compounds were dissolved in DMSO to a final concentration of 10 mmol/l and stored at −20°C when not in use.